TLRY
TLRY
NASDAQ · Pharmaceuticals

Tilray Brands Inc

$4.57
+0.13 (+2.93%)
As of Aug 8, 10:14 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.12B
Net Income
-148,172,517
Gross Margin
28.4%
Profit Margin
-13.3%
Rev Growth
+13.4%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 28.4% 28.4% 58.9% 58.9%
Operating Margin -6.9% -6.2% 36.6% 37.4%
Profit Margin -13.3% -12.6% 27.4% 25.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.12B 985.00M 180.40M 169.99M
Gross Profit 317.90M 280.23M 106.25M 100.12M
Operating Income -76,876,340 -60,991,454 66.09M 63.51M
Net Income -148,172,517 -117,555,769 49.45M 42.44M
Gross Margin 28.4% 28.4% 58.9% 58.9%
Operating Margin -6.9% -6.2% 36.6% 37.4%
Profit Margin -13.3% -12.6% 27.4% 25.0%
Rev Growth +13.4% +13.4% -1.4% +19.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 55.78M 55.78M 368.43M 383.92M
Total Equity 256.12M 256.12M 614.67M 608.97M
D/E Ratio 0.22 0.22 0.60 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -53,030,882 -44,410,558 94.91M 94.57M
Free Cash Flow 60.57M 46.11M